Higher BCR diversity, which is expected to increase the chance of tumor antigen uptake and presentation to T cells, is significantly correlated with longer OS after ICI therapy both in the bulk and single-cell RNA-seq cohorts of melanoma patients. The gene discussed is BCR; the disease is melanoma.